CLINICAL OUTCOME OF FEBRILE NEUTROPENIA IN CHILDREN WITH CANCER USING CEFTAZIDIME AND AMINOGLYCOSIDES

REFERENCES

• Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2002; CD003038
   Google Scholar
• Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176–189
   PubMed Web of Science ®Google Scholar
• Hughes W T, Armstrong D, Bodey G P. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551–573
   PubMed Web of Science ®Google Scholar
• Rolston K V, Berkey P, Bodey G P. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283–291
   PubMed Web of Science ®Google Scholar
• Paterson D L, Ko W C, Von Gottberg A. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26–32
   PubMed Web of Science ®Google Scholar
• Lan C K, Hsueh P R, Wong W W. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms. J Microbiol Immunol Infect 2003; 36: 182–186
   PubMedGoogle Scholar
• Ariffin H, Navaratnam P, Mohamed M. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000; 4: 21–25
   PubMedGoogle Scholar
• Zinner S H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490–494
   PubMed Web of Science ®Google Scholar
• Richard P, Amador Del Valle G, Moreau P. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995; 345: 1607–1609
   PubMed Web of Science ®Google Scholar
• Jones R N. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29: 495–502
   PubMed Web of Science ®Google Scholar
• Maipang M, Wongchanchailert M, Laosombat V, Pruekprasert P. Fever and neutropenia in paediatric cancer patients. Songkla Med J 1990; 8: 275–281
   Google Scholar
• Jittithaworn P, Preukprasert P. Febrile Neutropenia in Pediatric Cancer Patients. Thesis, Songkhla: Prince of Songkla University. 2003
   Google Scholar
• Junquera S, Loza E, Baquero F. [Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections.] Enferm Infecc Microbiol Clin 2005; 23: 197–201
   Google Scholar
• Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991; 10: 918–923
   PubMed Web of Science ®Google Scholar
• Charnas R, Luthi A R, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J 1997; 16: 346–353
   PubMedGoogle Scholar
• Fanci R, Paci C, Martinez R L. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy. J Chemother 2000; 12: 232–239
   PubMed Web of Science ®Google Scholar
• Cometta A, Glauser M P. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 1996; 8: 375–381
   PubMed Web of Science ®Google Scholar
• Miranda-Novales M G, Belmont-Martinez L, Villasis-Keever M A. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever: risk factors for treatment failure. Arch Med Res 1998; 29: 331–335
   PubMed Web of Science ®Google Scholar
• Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. Clin Infect Dis 2004; 39(Suppl 1)S53–S55
   Google Scholar
• Donowitz G R, Maki D G, Crnich C J, Pappas P G, Rolston K V. Infections in the neutropenic patient—new views of an old problem. Hematology Am Soc Hematol Educ Program 2001; 113–139
   PubMedGoogle Scholar
• Wust J, Frei R. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of gram-positive and gram-negative bacteria from hospitalized patients in Switzerland. Clin Microbiol Infect 1999; 5: 262–269
   PubMedGoogle Scholar
• Wey S B, Mori M, Pfaller M A, Woolson R F, Wenzel R P. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642–2645
   PubMed Web of Science ®Google Scholar
• Elting L S, Rubenstein E B, Rolston K. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 2000; 18: 3699–3706
   PubMed Web of Science ®Google Scholar
• Jitsurong S, Yodsawat J. Prevalence of extended-spectrum beta-lactamases (ESBLs) produced in blood isolates of gram-negative bacteria in a teaching hospital in southern Thailand. Southeast Asian J Trop Med Public Health 2006; 37: 131–135
   PubMedGoogle Scholar
• Rice L B, Eckstein E C, DeVente J, Shlaes D M. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118–124
   PubMed Web of Science ®Google Scholar
• Mebis J, Goossens H, Bruyneel P. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998; 12: 1627–1629
   PubMed Web of Science ®Google Scholar
• Paterson D L, Ko W C, Von Gottberg A. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31–37
   PubMed Web of Science ®Google Scholar
• Fanci R, Paci C, Leoni F, Casini C, Longo G. Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial. J Chemother 2003; 15: 253–259
   PubMed Web of Science ®Google Scholar
• Erman M, Akova M, Akan H. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study. Scand J Infect Dis 2001; 33: 827–831
   PubMed Web of Science ®Google Scholar
• Corapcioglu F, Sarper N. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol 2005; 22: 59–70
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner S, de Bock R. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39: 445–452
   PubMed Web of Science ®Google Scholar
• Marie J P, Vekhoff A, Cony-Makhoul P. [Piperacilline/tazobactam combination + amikacin versus ceftazidime + amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d’etude des Aplasies Febriles.] Presse Med 1995; 24: 397–401
   Google Scholar
• Cometta A, Calandra T, Gaya H. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Chemother 1996; 40: 1108–1115
   PubMed Web of Science ®Google Scholar
• de la Camara R, Figuera A, Sureda A. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica 1997; 82: 668–675
   PubMedGoogle Scholar
• Behre G, Link H, Maschmeyer G. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol 1998; 76: 73–80
   PubMed Web of Science ®Google Scholar
• Agaoglu L, Devecioglu O, Anak S. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13: 281–287
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki D G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519–527
   PubMed Web of Science ®Google Scholar